E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Have a histologic or cytologic diagnosis of advanced or metastatic malignancies for which no life-prolonging therapy exists and have been previously enrolled and completed therapy in an enzastaurin clinical pharmacology and biopharmaceutics study. |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To collect further basic safety data on patients with advanced or metastatic malignancies treated with enzastaurin. |
|
E.2.2 | Secondary objectives of the trial |
To document antitumor activity that may be observed with enzastaurin.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
[1] Have previously been enrolled and completed protocol therapy in an enzastaurin clinical pharmacology and biopharmaceutics study. [2] Have a histologic or cytologic diagnosis of advanced or metastatic malignancies or which no life-prolonging therapy exists. This may include patients with treated, stable brain metastases. [3] Have measurable or non-measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) (Protocol Attachment S001.4). [4] Have a performance status of 0 to 2 on the Eastern Cooperative Oncology Group (ECOG) Scale (Protocol Attachment S001.2). [5] Have adequate bone marrow reserve and organ function as follows: • Absolute neutrophil count (ANC) >1.5 x 109/L and platelets >100 x 109/L. • Hepatic: Total bilirubin <2 times upper limits of normal (ULN), ALT, and AST <3 times ULN (or <5 times ULN in case of known liver involvement). • Renal: serum creatinine <1.5 mg/dL. [6] Have discontinued all previous therapies for cancer, except for protocol therapy from a lead-in study (that is, JCAV, JCAY, or another enzastaurin clinical pharmacology and biopharmaceutics study). Any other previous therapies including chemotherapy, radiotherapy, anticancer hormone therapy, or other investigational therapy must be discontinued for at least 4 weeks prior to study enrollment and patient must have recovered from any acute effects of previous treatment. [7] Reproductive potential must be either terminated (by surgery, radiation, or menopause) or attenuated by the use of an approved contraceptive method including intrauterine or barrier devices) during and for 3 to 6 months following the study. [8] Men and women at least 18 years of age. [9] Have given written informed consent. [10] Exhibit patient compliance and geographic proximity that allow for adequate follow-up. |
|
E.4 | Principal exclusion criteria |
[11] Have received treatment within the last 30 days with a drug other than enzastaurin that has not received regulatory approval for any indication at the time of study entry. [12] Women who are pregnant or breastfeeding. [13] Symptomatic central nervous system (CNS) neoplasm. (Patients who have stable CNS neoplasm on steroid medication may be included.) [14] Serious concomitant disorder, including active bacterial, fungal, or viral infection, incompatible with the study (at the discretion of the investigator). [15] Second primary malignancy that could affect compliance with the protocol or interpretation of the results. Patients with adequately treated basal cell carcinoma of the skin or who have had another malignancy in the past, but have been disease-free for more than 2 years, are eligible. [16] Electrocardiogram (ECG) abnormalities indicative of cardiac disease (at the discretion of the investigator). [17] For patients receiving EIAEDs: Patients must discontinue EIAEDs at least 14 days prior to study enrollment. The investigator may prescribe non-EIAEDs (see Attachment S001.5). However if a patient requires EIAED therapy while on study, the patient will not be discontinued from the study. [18] Inability to swallow tablets. [19] Concurrent administration of any other antitumor therapy. |
|
E.5 End points |
E.5.1 | Primary end point(s) | |
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
Safety/Efficacy extension study |
|
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 5 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Patients will continue to receive enzastaurin until it is approved for marketing for the respective indication, until disease progression, unacceptable toxicity, or other criteria (as specified in Section 4.3) apply, or until Lilly stops the study.
The end of the trial is defined as the last visit of the last patient undergoing the trial. This visit will occur within approximately 30 days following the last enzastaurin dose, when another therapy is initiated, or when the patient dies. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |